Other aims are to learn how effective treatment with TAK-007 is in adults with refractory LN, what effects TAK-007 has on the human body, and whether participants will produce antibodies against TAK-007. conditions: Refractory Lupus Nephritis studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: TAK-007 name: Chemotherapy Agents measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) measure: Number of Participants With Dose Limiting Toxicities (DLTs) measure: Cmax: Maximum Observed Plasma Concentration for TAK-007 measure: Tmax: Time to Reach the Cmax for TAK-007 measure: Tlast: Time of Last Measurable Concentration Above the Lower Limit of Quantitation for TAK-007 measure: AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-007 measure: Change From Baseline in CD19+ B Cell Counts measure: Duration of B Cell Depletion measure: Change From Baseline in Plasma Cytokine Levels measure: Change From Baseline in Physician's Global Assessment (PGA) Score measure: Percentage of Participants Achieving a Reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Relative to Baseline measure: Percentage of Participants Achieving Complete Renal Response (CRR) measure: Time to CRR measure: Duration of CRR measure: Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) measure: Time to LLDAS measure: Duration of LLDAS measure: Percentage of Participants Meeting the Definition of Remission in SLE (DORIS) Criteria measure: Time to DORIS Remission measure: Duration of DORIS Remission measure: Change From Baseline in Anti-Double Stranded Deoxyribonucleic Acid (dsDNA) Levels measure: Change From Baseline in Antinuclear Antibody (ANA) Levels measure: Change From Baseline in Proteinuria Levels measure: Change From Baseline in Creatinine Levels measure: Change From Baseline in eGFR measure: Change From Baseline in Complement (C3, C4) Levels measure: Percentage of Participants With Antidrug Antibodies Categorized as Anti-Human Leukocyte Antigen (HLA) and Anti- Chimeric Antigen Receptor (CAR) measure: Percentage of Participants With Replication Competent Retrovirus (RCR) in Blood sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Michigan city: Ann Arbor state: Michigan zip: 48109 country: United States name: Site Contact role: CONTACT phone: 888-229-3065 email: madisonj@med.umich.edu name: Jacqueline Madison role: PRINCIPAL_INVESTIGATOR lat: 42.27756 lon: -83.74088 facility: University of Rochester city: Rochester state: New York zip: 14642 country: United States name: Site Contact role: CONTACT phone: 585-486-0901 email: christopher_palma@urmc.rochester.edu name: Christopher Palma role: PRINCIPAL_INVESTIGATOR lat: 43.15478 lon: -77.61556 facility: UT Health Houston city: Houston state: Texas zip: 77030 country: United States name: Site Contact role: CONTACT phone: 713-486-3100 email: Meera.g.subash@uth.tmc.edu name: Meera Subash role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False